A citation-based method for searching scientific literature

Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu, Kaori Suzuki, Kuniaki Saito, Keiichi Kobayashi, Fumi Higuchi, Takeo Uzuka, Ryohei Otani, Kaoru Tamura, Kazutaka Sumita, Makoto Ohno, Yasuji Miyakita, Naoki Kagawa, Naoya Hashimoto, Ryusuke Hatae, Koji Yoshimoto, Naoki Shinojima, Hideo Nakamura, Yonehiro Kanemura, Yoshiko Okita, Manabu Kinoshita, Kenichi Ishibashi, Tomoko Shofuda, Yoshinori Kodama, Kanji Mori, Yusuke Tomogane, Junya Fukai, Koji Fujita, Yuzo Terakawa, Naohiro Tsuyuguchi, Shusuke Moriuchi, Masahiro Nonaka, Hiroyoshi Suzuki, Makoto Shibuya, Taketoshi Maehara, Nobuhito Saito, Motoo Nagane, Nobutaka Kawahara, Keisuke Ueki, Toshiki Yoshimine, Etsuo Miyaoka, Ryo Nishikawa, Takashi Komori, Yoshitaka Narita, Koichi Ichimura. Acta Neuropathol Commun 2016
Times Cited: 116



Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
Times Cited: 110




List of shared articles



Times cited

Human TERT promoter mutations as a prognostic biomarker in glioma.
Branka Powter, Sarah A Jeffreys, Heena Sareen, Adam Cooper, Daniel Brungs, Joseph Po, Tara Roberts, Eng-Siew Koh, Kieran F Scott, Mila Sajinovic,[...]. J Cancer Res Clin Oncol 2021
1

TERT Promoter Alterations in Glioblastoma: A Systematic Review.
Nathalie Olympios, Vianney Gilard, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Maxime Fontanilles. Cancers (Basel) 2021
0

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Yusuke Funakoshi, Nobuhiro Hata, Kosuke Takigawa, Hideyuki Arita, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Aki Sako, Toru Umehara,[...]. Cancer Med 2021
2

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Kosuke Takigawa, Nobuhiro Hata, Yuhei Michiwaki, Akio Hiwatashi, Hajime Yonezawa, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Yusuke Funakoshi,[...]. J Neurooncol 2021
1

Intraventricular mucin-producing glioblastoma arising in the septum pellucidum at the frontal horn of the lateral ventricle: A case report.
Kosuke Takigawa, Nobuhiro Hata, Yuhei Sangatsuda, Satoshi O Suzuki, Noritoshi Sirozu, Ryusuke Hatae, Yojiro Akagi, Toru Iwaki, Shinji Nagata, Masahiro Mizoguchi. Neuropathology 2021
0

Prognostic and Predictive Biomarkers in Gliomas.
Paulina Śledzińska, Marek G Bebyn, Jacek Furtak, Janusz Kowalewski, Marzena A Lewandowska. Int J Mol Sci 2021
0

First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Nobuhiro Hata, Masahiro Mizoguchi, Daisuke Kuga, Ryusuke Hatae, Yojiro Akagi, Yuhei Sangatsuda, Takeo Amemiya, Yuhei Michiwaki, Yutaka Fujioka, Kosuke Takigawa,[...]. J Neurooncol 2020
9

The Solo Play of TERT Promoter Mutations.
François Hafezi, Danielle Perez Bercoff. Cells 2020
8

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
Radia M Johnson, Heidi S Phillips, Carlos Bais, Cameron W Brennan, Timothy F Cloughesy, Anneleen Daemen, Ulrich Herrlinger, Robert B Jenkins, Albert Lai, Christoph Mancao,[...]. Neuro Oncol 2020
5

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma.
Zensho Kikuchi, Ichiyo Shibahara, Tetsu Yamaki, Ema Yoshioka, Tomoko Shofuda, Rintaro Ohe, Ken-Ichiro Matsuda, Ryuta Saito, Masayuki Kanamori, Yonehiro Kanemura,[...]. Neurooncol Adv 2020
1

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
Sirui Ma, Soumon Rudra, Jian L Campian, Sonika Dahiya, Gavin P Dunn, Tanner Johanns, Michael Goldstein, Albert H Kim, Jiayi Huang. Neurooncol Adv 2020
9

Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
K Yamashita, R Hatae, A Hiwatashi, O Togao, K Kikuchi, D Momosaka, Y Yamashita, D Kuga, N Hata, K Yoshimoto,[...]. Diagn Interv Imaging 2019
12

Genomics-Enabled Precision Medicine for Cancer.
Alison Roos, Sara A Byron. Cancer Treat Res 2019
3

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
Saumya R Bollam, Michael E Berens, Harshil D Dhruv. Curr Neurol Neurosci Rep 2018
3

Telomere Maintenance Mechanisms in Cancer.
Tiago Bordeira Gaspar, Ana Sá, José Manuel Lopes, Manuel Sobrinho-Simões, Paula Soares, João Vinagre. Genes (Basel) 2018
48

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Katharina Neumayer, Lucia Kastler, Johannes Gojo, Christine Pirker, Josef Pichler, Serge Weis, Rajiv Kumar, Gerald Webersinke,[...]. Neuro Oncol 2018
41